Ticlopidine versus aspirin for stroke prevention: On-treatment results from the ticlopidine aspirin stroke study.
Từ khóa
trừu tượng
Ticlopidine is the newest antiplatelet agent that has been compared with aspirin for stroke prevention. Results from the intent-to-treat analysis of the Ticlopidine Aspirin Stroke Study, a randomized, triple-blind trial, showed ticlopidine to be more effective than aspirin for the prevention of threatened stroke. We present the on-treatment analysis from this study in 3,034 eligible patients receiving either ticlopidine (500 mg daily) or aspirin (1,300 mg daily). Follow-up was for 2-6 years. During year 1, the high-risk period for stroke in patients with threatened stroke, ticlopidine reduced the risk of stroke over aspirin by 48% (p = 0.0004: the event rates were 3.4 and 6.4, respectively). The overall risk for fatal and nonfatal stroke was 27% (95% confidence intervals were 6.6 and 42.3), less with ticlopidine than with aspirin. Ticlopidine significantly decreased the risk of fatal and nonfatal stroke in both sexes and has a different adverse effect profile than aspirin. More adverse effects, primarily diarrhea and rash, were reported with ticlopidine.